Stock Taper
SCREENER COMPARE ANY 2 STOCKS
IKT
INHIBIKASE THERAPEUTICS, INC.
NASDAQ
$2.41
▼ DOWN 2.43% (-0.06)

KEY STATISTICS

Market Cap$318.20 M
52w High$2.54
52w Low$1.33
Dividend Yield—
Frequency—
P/E-5.60
Volume307.96K
Shares Out.132.03M

COMPANY

LEADERSHIP

Mark T. Iwicki
CHIEF EXECUTIVE
Mark T. Iwicki

COMPENSATION 2026

Salary$624,208
Stock Awards$0
Incentive Plan Pay$532,500
All Other Comp.$0
Total$30,586,007

ABOUT

SECTOR
Healthcare
WENT PUBLIC
December 23, 2020
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
35

PRICE TARGET

Target High$8.00
Target Low$5.00
Target Median$6.50
Target Consensus$6.50

UPCOMING EARNINGS

DateNov 13, 2026
DayFriday
Rev. Est.—
NOV
13
FRI

SPLIT RECORD

DATETYPERATIO
2023-06-30Reverse1:6

PRICE

$2.41 ▼ DOWN 2.43% (−$0.06)
OVERLAYS
$2.40$2.43$2.469:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM2.41

About Inhibikase Therapeutics, Inc.

https://www.inhibikase.com ↗

Inhibikase Therapeutics, Inc. is a clinical-stage biotech developing Parkinson's and neurological disorder therapeutics, including IkT-148009 and IkT-001Pro, with collaborations across leading universities.

INDUSTRY

Biotechnology

A PRODUCT INHIBIKASE THERAPEUTICS, INC. IS KNOWN FOR

IKT-001
IKT-001

IKT-001 is a prodrug of imatinib developed for Pulmonary Arterial Hypertension, offering improved safety, now advancing to Phase 3 after discontinuing its Parkinson's program.

COMPETITORS

COMPETITOR
DNLI COMPARE
GOSS COMPARE
PRTA COMPARE
VYGR COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
49
LISTED HERE
10
RANKED BY POSITION SIZE
VTS.AX
0.00% · 3.8M
IWM
0.01% · 3.0M
SBIO
0.16% · 163.4K
R2SC.L
0.01% · 140.8K
XRS2.DE
0.01% · 118.8K
AVSC
0.01% · 101.3K
RSSL
0.01% · 57.6K
DFMC
0.00% · 10.9K
URTY
0.00% · 4.9K
RTYS.L
0.01% · 0

INSTITUTIONAL OWNERSHIP

SHARES OWNED
61.99%
HOLDERS
106
TOP 12 OF 106 · RANKED BY POSITION SIZE
Sands Capital Ventures, LLC
13.0M sh · $21.87M
Soleus Capital Management, L.P.
10.9M sh · $18.27M
Fairmount Funds Management LLC
8.6M sh · $14.49M
Adar1 Capital Management, LLC
8.1M sh · $16.53M
Blackrock, Inc.
6.3M sh · $10.59M
Blackstone Inc.
5.9M sh · $9.98M
Siren, L.L.C.
5.8M sh · $9.83M
Perceptive Advisors LLC
5.4M sh · $11.11M
Commodore Capital LP
5.4M sh · $9.07M
Vanguard Group Inc
4.6M sh · $9.35M
Nantahala Capital Management, LLC
3.9M sh · $8.06M
Saturn V Capital Management LLC
3.9M sh · $6.49M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book3
Overall Score2

INSIDER TRADES

★
DIRECTOR
BERMAN DENNIS N
Sale · 21.9K shares
2026-07-30
★
10 PERCENT OWNER
RA CAPITAL MANAGEMENT, L.P.
Purchase · 18.0M shares
2026-07-29
★
10 PERCENT OWNER
RA CAPITAL MANAGEMENT, L.P.
Sale · 18.0M shares
2026-07-29
★
DIRECTOR
BERMAN DENNIS N
Purchase · 21.9K shares
2026-07-30

SECTORS PEERS

PEERPRICE
AGEN$7.66COMPARE
TTRX$9.84COMPARE
GLSI$15.67COMPARE
SRZN$22.42COMPARE
ENTX$3.03COMPARE
CGTX$1.02COMPARE
EXOZ$7.17COMPARE
ESLA$0.71COMPARE